McCormick Place

BriaCell Presents Clinical Efficacy Data at ASCO 2024

Retrieved on: 
月曜日, 6月 3, 2024
MD, Breast cancer, ASCO, Patient, Annual general meeting, McCormick Place, Cancer, Safety, Immunotherapy, Society, Therapy, Mayo Clinic, Palliative care, Spacecraft, NK, BCT, CPI, TSX, University, Physician, Principal investigator, Pharmaceutical industry

Two poster sessions, one abstract, and one oral presentation session (by Principal Investigator and Professor of Oncology, Mayo Clinic, Saranya Chumsri, MD), will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place today June 3, 2024 at McCormick Place, Chicago, IL.

Key Points: 
  • Two poster sessions, one abstract, and one oral presentation session (by Principal Investigator and Professor of Oncology, Mayo Clinic, Saranya Chumsri, MD), will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place today June 3, 2024 at McCormick Place, Chicago, IL.
  • “We are very impressed with both clinical efficacy and safety data in these heavily pretreated patients.
  • “Antibody-drug conjugates (ADCs) and immune checkpoint Inhibitors (CPIs) have emerged as the latest therapies to treat these patients.
  • Discovering new strategies, in order to enhance the responsiveness of various subtypes of breast cancer to immunotherapy, presents as a therapeutic opportunity.

Precede Biosciences Presents New Data at ASCO 2024 Demonstrating Accurate HER2 Status Detection Across Multiple Cancers and the Ability to Quantify ER Pathway Activation in Breast Cancer from a Simple Blood Test

Retrieved on: 
日曜日, 6月 2, 2024
Annual general meeting, McCormick Place, MD, ASCO, Cancer, Society, Radio, Patient, Dana–Farber Cancer Institute

“There is a significant clinical need to understand target expression in cancers that can benefit from directed therapeutic modalities such as antibody drug conjugates, radio conjugates, immuno-conjugates, and cell therapies,” said Carl Barrett, Chief Scientific Officer of Precede Bio.

Key Points: 
  • “There is a significant clinical need to understand target expression in cancers that can benefit from directed therapeutic modalities such as antibody drug conjugates, radio conjugates, immuno-conjugates, and cell therapies,” said Carl Barrett, Chief Scientific Officer of Precede Bio.
  • “Data presented at ASCO demonstrate the potential of Precede Bio’s blood-based approach to selecting patients for treatment with HER2-targeting therapies and next generation anti-endocrine therapies.”
    “The data presented at ASCO highlight the potential of a novel blood-based epigenomic liquid biopsy platform to simultaneously predict ER status and infer activity of the ER signaling pathway in patients with metastatic breast cancer,” said Stefania Morganti, MD, Clinical Research Fellow at Dana-Farber Cancer Institute.
  • “After further validation, this minimally invasive assay could become a valuable tool for guiding treatment selection.
  • Given the swift advancement of multiple novel treatment options, including next generation endocrine therapies and antibody-drug conjugates, there is an urgent need for novel predictive biomarkers to best select treatments for patients with metastatic breast cancer.”
    Data presented at the 2024 ASCO Annual Meeting can be found in the presentations section of the company website and are linked below:

Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting

Retrieved on: 
土曜日, 6月 1, 2024
Aes, Bronchospasm, Comment, Patient, Annual general meeting, McCormick Place, Sant Joan, DCH, Cancer, Abdominal pain, Society, Therapy, Radioimmunotherapy, Bone marrow, Disease, Granulocyte-macrophage colony-stimulating factor, Pain, Hypotension, MBBS, Poster, MSK, MRCP, Pharmaceutical industry

The results are summarized in poster presentations scheduled to be presented today, June 1, 2024, at the 2024 American Society of Clinical Oncology (“ASCO”) Annual Meeting in Chicago, IL.

Key Points: 
  • The results are summarized in poster presentations scheduled to be presented today, June 1, 2024, at the 2024 American Society of Clinical Oncology (“ASCO”) Annual Meeting in Chicago, IL.
  • The Trial 201 prespecified interim analysis achieved a 50% overall response rate (“ORR”) in 26 out of 52 patients.
  • Nearly a quarter of patients achieved their first complete response (“CR”) or partial response (“PR”) after three or more cycles of naxitamab therapy.
  • These results support the rationale for extended naxitamab therapy in patients who do not achieve a CR or PR at first assessment.

Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting

Retrieved on: 
土曜日, 6月 1, 2024
Lanthanum, Comment, DOTA, GD2, Patient, Annual general meeting, McCormick Place, Cancer, DCH, Society, Therapy, Radioimmunotherapy, Lutetium, Diagnosis, MBBS, MSK, MRCP, Medical device

In this analysis, GD2-SADA showed tight binding to cell lines expressing GD2, a glycolipid implicated in the malignant transformation of multiple solid tumors.

Key Points: 
  • In this analysis, GD2-SADA showed tight binding to cell lines expressing GD2, a glycolipid implicated in the malignant transformation of multiple solid tumors.
  • Previous studies have shown that the unbound GD2-SADA protein disassembles over time, facilitating clearance by the kidneys.
  • The analysis further demonstrated high-affinity binding of GD2-SADA to DOTA complexes chelated with lutetium and lanthanum, among other lanthanide metals.
  • Researchers at MSK, including Dr. Nai-Kong Cheung, developed the SADA technology for radioimmunotherapy, which is exclusively licensed by MSK to Y-mAbs.

Sermonix Pharmaceuticals to Present Poster on ELAINE-3 Trial in Progress at ASCO 2024

Retrieved on: 
木曜日, 5月 30, 2024
McCormick Place, Fulvestrant, Safety, Breast cancer, MBC, Neoplasm, ASCO, ESR1, Society, Mutation, Therapy, Eli Lilly, Quality of life, Pharmaceutical industry

COLUMBUS, Ohio, May 30, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mBC), today announced it will present a poster updating the progress of its Phase 3 ELAINE-3 clinical trial at the annual meeting of the American Society of Clinical Oncology (ASCO).

Key Points: 
  • COLUMBUS, Ohio, May 30, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mBC), today announced it will present a poster updating the progress of its Phase 3 ELAINE-3 clinical trial at the annual meeting of the American Society of Clinical Oncology (ASCO).
  • ASCO 2024 will be held May 31-June 4, 2024, at McCormick Place in Chicago.
  • “Sermonix looks forward to updating our peers at ASCO 2024 about the progress of ELAINE-3, which is actively enrolling in the U.S., Canada, Europe and Israel,” said Dr. David Portman, Sermonix founder and chief executive officer.
  • We are excited to gain a greater understand of lasofoxifene’s potential as ELAINE-3 progresses, and hopefully bring it one important step closer to patients.”

Indaptus Therapeutics to Present New Cohort Data Confirming Original “Pulse-Prime” Hypothesis Via Phase 1 Clinical Trial of Decoy20 at the American Society of Clinical Oncology Annual Meeting

Retrieved on: 
水曜日, 5月 29, 2024
McCormick Place, LPS, Patient, Pharmacokinetics, Plasma, Cytokine, Therapy, Blood, Chemokine, Viral, Poster, Society

The conference will be held in Chicago at McCormick Place from May 31-June 4, 2024 where full data will be presented.

Key Points: 
  • The conference will be held in Chicago at McCormick Place from May 31-June 4, 2024 where full data will be presented.
  • The data presented include the pharmacokinetics and immune response observed in both cohorts in the ongoing Phase 1 trial for Decoy20.
  • Adverse effects were generally tolerable and resolved with or without treatment within 90 minutes to 3 days.
  • We continue the Phase 1 clinical trial with the first multi-dose cohort and expect to provide updates on progress throughout the year.”

Pacylex Pharmaceuticals Reports Zelenirstat Phase 1 Safety and Efficacy Data at ASCO 2024

Retrieved on: 
金曜日, 5月 24, 2024
McCormick Place, Cancer, Trial of the century, EGFR, Patient, ASCO, VEGFR, Society, NMT, Annual general meeting

Edmonton, Alberta--(Newsfile Corp. - May 24, 2024) - Pacylex Pharmaceuticals Inc. (Pacylex) is a clinical-stage pharmaceutical company developing N-myristoyltransferase (NMT) inhibitors as targeted therapies for the treatment of hematologic cancers and solid tumors.

Key Points: 
  • Edmonton, Alberta--(Newsfile Corp. - May 24, 2024) - Pacylex Pharmaceuticals Inc. (Pacylex) is a clinical-stage pharmaceutical company developing N-myristoyltransferase (NMT) inhibitors as targeted therapies for the treatment of hematologic cancers and solid tumors.
  • Today Pacylex announced that complete Phase 1 clinical study results for zelenirstat, a proprietary, potent, NMTi, will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4, 2024, at McCormick Place in Chicago, Illinois.
  • Zelenirstat was well tolerated, and adverse events were primarily gastrointestinal side effects, most of which resolved spontaneously without dose reduction.
  • Zelenirstat inhibits myristoylation of multiple oncogenic targets leading to the inhibition of the signaling of validated colon cancer targets EGFR and VEGFR.

Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
木曜日, 5月 23, 2024
CHRS, Immunosuppression, Half-life, McCormick Place, Patient, CCR8, Immunoglobulin G, TME, Tumor microenvironment, Neoplasm, Poster, Safety, Death, PD-1, GPCR, ASCO, Infrared spectroscopy correlation table, Aes, IO, SAE, Vaccine

REDWOOD CITY, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced clinical data from the CHS-114, single agent dose escalation stage of its Phase 1 study at the ASCO Annual Meeting, taking place May 31 to June 4, 2024, at McCormick Place in Chicago. CHS-114 is a novel afucosylated human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that selectively and potently targets human CCR8 with no off-target binding. CCR8 is a G protein-coupled receptor (GPCR) that shows preferential expression on tumor resident Treg cells and has promise as a drug target for selectively targeting immune suppression in the tumor microenvironment (TME) without broadly depleting Treg cells, which has the known unwanted side effect of autoimmune activation.

Key Points: 
  • “The Phase 1 preliminary dose escalation results are an important milestone as we progress our innovative I-O pipeline.
  • Abstract # 2664: Preliminary Results of a Phase 1, First-in-human, Dose Escalation Study of the Anti-CCR8 Cytolytic Antibody, CHS-114 (formerly SRF114) in Patients with Advanced Solid Tumors.
  • Preliminary results and acceptable safety profile support further evaluation of CHS-114 in combination treatment with toripalimab and other I-O agents.
  • In 19 patients evaluable for response, no objective responses were yet noted, while the stable disease rate was 47%.

Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting

Retrieved on: 
木曜日, 5月 23, 2024
IOV, Interleukin, McCormick Place, ICI, Patient, TIL, Pembrolizumab, Cohort, Food, Clinical trial, CDT, FDA, EDT, Disease, Safety, SAN, RECIST, Cancer, Melanoma, ASCO, Webcast, Pharmaceutical industry

SAN CARLOS, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced updated clinical data for lifileucel in combination with pembrolizumab in frontline advanced melanoma, as well as translational data, for the upcoming 2024 ASCO Annual Meeting to be held May 31 – June 4, 2024, at McCormick Place in Chicago, IL and online.

Key Points: 
  • Unprecedented response rates, as well as deep and durable responses, were observed in patients with frontline advanced melanoma who were naïve to immune checkpoint inhibitor (ICI) therapy.
  • Confirmed ORR was 65.2%, including 7 (30.4%) complete responses and 8 (34.8%) partial responses by RECIST v1.1.
  • TILVANCE-301 is a global, randomized, registrational Phase 3 trial to support accelerated and full U.S. approvals of lifileucel in combination with pembrolizumab in frontline advanced melanoma.
  • The live and archived webcast can be accessed in the Investors section of the Company’s website, IR.Iovance.com for one year.

Blender Bites Attends 2024 National Restaurant Association Show, the Largest Annual Foodservice Event in the Western Hemisphere

Retrieved on: 
火曜日, 5月 21, 2024
McCormick Place, Restaurant, University, Airport, Marketing, Growth, WKN, FWB, BITE, National Restaurant Association

The event will take place at McCormick Place, Chicago, Illinois, US, from May 18-21, 2024.

Key Points: 
  • The event will take place at McCormick Place, Chicago, Illinois, US, from May 18-21, 2024.
  • Participating in the National Restaurant Association Show provides invaluable exposure to the foodservice industry, and the Company expects to connect with key players, including commercial chains, commercial independents, and non-commercial businesses.
  • “We are incredibly excited to showcase our innovative, plant-based products at the 2024 National Restaurant Association Show.
  • We look forward to building meaningful connections and exploring new avenues for growth and success at the 2024 National Restaurant Association Show.”